A survey by the Brazilian Sleep Association (ABS) reveals that 73 million Brazilians suffer from insomnia. They sleep poorly and, consequently, deal with damage to both physical and mental health. Approved in 2019 by the Food and Drug Administration (FDA), a regulatory agency in the United States, lemborexant, touted as the best medication for insomnia, is now being analyzed by the National Health Surveillance Agency (Anvisa) and can reach pharmacies in the country. in 2023, says the pharmaceutical company that produces the drug, the Japanese company Eisai.
The most prescribed drugs in Brazil, benzodiazepines, instead of inhibiting wakefulness, induce a neurotransmitter called gaba, which reduces the activity of the nervous system, causing a feeling of relaxation and sleep. The problem is that its chronic use causes dependence and increases the risk of dementia.